Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey
- TURAN, İLKER
- Danis, NİLAY
- Akarca, Ulus S.
- Sipahi, Oguz R.
- Tasbakan, Meltem
- Tekin, Fatih
- Oruc, Nevin
- Vardar, Rukiye
- ÜNAL, NALAN GÜLŞEN
- Pullukcu, Husnu
- Gunsar, Fulya
- Ersoz, Galip
- Yamazhan, Tansu
Publication date
March 2020
DOIAbstract
Background/Aims: Ledipasvir (LDV) and sofosbuvir (SOF) as single-tablet regimen (STR) has been approved for treatment of chronic HCV infection (CHC) for treatment-naive or experienced cirrhotic or non-cirrhotic patients. Our aim was to analyse the effectiveness and safety of 12-24 weeks treatment of LDV/SOF (90mg/400 mg)+/- ribavirin in a real-life setting in Turkey
Add to ORKG